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Cobra venom factor (CVF) is a functional analog of
human complement component C3b, the active frag-
ment of C3. Similar to C3b, in human andmammalian
serum, CVF binds factor B, which is then cleaved by
factor D, giving rise to the CVFBb complex that
targets the same scissile bond in C3 as the authentic
complement convertases C4bC2a and C3bBb.
Unlike the latter, CVFBb is a stable complex and an
efficient C5 convertase. We solved the crystal struc-
ture of CVF, isolated from Naja naja kouthia venom,
at 2.6 A˚ resolution. The CVF crystal structure, an
intermediate between C3b and C3c, lacks the TED
domain and has the CUB domain in an identical posi-
tion to that seen in C3b. The similarly positioned CUB
and slightly displaced C345c domains of CVF could
play a vital role in the formation of C3 convertases
by providing important primary binding sites for
factor B.
INTRODUCTION
Cobra venom factor (CVF), a disulfide-linked three-chain 149 kDa
nontoxic glycoprotein, is an activator ofmammalian complement
present in cobra venom. It is a functional homologof complement
component C3b, an active fragment of C3. Similar to C3b, CVF
binds to serum factor B in the presence of Mg2+. The resulting
complex has weak C3-convertase activity (Xu et al., 2001) but
subsequent cleavage of factor B by factor D gives rise to CVFBb,
an efficient C3 convertase targeting the same scissile bond of C3
as authentic complement convertases (Figure 1A). Although the
closely related convertases C3bBb and CVFBb share identical
restricted substrate specificity residing in their Bb subunit, they
differ in other biochemical properties. Interesting differences
include: (1) C3bBb is very short lived with a half-life of 1.5 min
at 37C (Medicus et al., 1976; Pangburn and Mu¨ller-Eberhard,
1986), whereas CVFBb is rather stable with a half-life of 7 hr at
room temperature and more than 20 days at 4C (Vogel and
Mu¨ller-Eberhard, 1982), though both C3bBb and CVFBb show
spontaneous decay dissociation into their two respectiveStructure 17subunits, which abolishes their enzymatic activity. (2) Factor H
disassembles C3bBb (Pangburn et al., 1977) and serves as
cofactor for the subsequent proteolytic inactivation of C3b by
factor I (Whaley and Ruddy, 1976), whereas CVFBb and CVF
are completely resistant to factors H and I (Alper and Balavitch,
1976; Lachmann and Halbwachs, 1975). (3) C3bBb requires an
additional C3b molecule to form an efficient C5 convertase
(Daha et al., 1976; Vogt et al., 1978), whereas CVF, from certain
cobra species like Naja naja kouthia forms the CVFBb complex
that can efficiently cleave C5 (DiScipio et al., 1983; von Zabern
et al., 1980).
Pro-C3 (1–1641) is processed into mature two-chain C3
(115 kDa a chain [650–1641] and 70 kDa b chain [1–645]) by
the removal of four arginine residues (646–649), whereas
pro-CVF (1–1620) is processed into its mature three-chain CVF
(70 kDa a chain [1–627], 48 kDa b chain [1242–1620], and
32 kDa g chain [711–962]) by proteolytic removal of C3a
(632–710)- and C3d (963–1241)-like domains and four arginine
residues (628–631) (Figure 1B). The pro-CVF contains 27
cysteine residues and their distribution is identical to those in
the C3 (Fritzinger et al., 1994). However, there are differences
in carbohydrate content and their sites. C3 has only 1.7% carbo-
hydrate content (Tomana et al., 1985), whereas CVF has 7.4%
(w/w) (Fritzinger et al., 1994; Gowda et al., 1992; Grier et al.,
1987; Vogel and Mu¨ller-Eberhard, 1984). Studies have shown
that the oligosaccharides of CVF are not required for its
complement-activating function (Gowda et al., 1994, 2001).
It has been suggested that the CVF structure may resemble
the inactive C3c fragment of C3 (Vogel et al., 1984). However,
as expected from the functional homology, CVF and C3b
molecules exhibit several similarities including amino acid
compositions, isoelectric points, circular dichroism spectra
and secondary structures, electron microscopic ultrastructures,
immunological cross-reactivity in the polypeptide, and carbohy-
drate moieties and N-terminal sequences (Vogel et al., 1984). On
the other hand, structural differences must exist between these
two molecules dictating different properties of their respective
convertases. Similar to C3, Pro-CVF also contains a thioester
site in its C3d-like region (Cys971 and Glu974), but this region is
removed during the processing toward CVF. Hence, the pre-
dicted C3c-like structure and observed C3b-like function of
CVF combined with a C3c-like resistance to inactivation by the
control proteins factors H and I need to be reconciled., 611–619, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 611
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depletion of serum complement activity both in vitro and in vivo.
This property has been exploited in numerous animal studies to
investigate the role of complement in host defense, immune
response, and pathogenesis of inflammatory diseases. CVF
has also been used for targeted complement activation by
coupling it to monoclonal antibodies or other targeting moieties
with specificity for targeted cells, such as cancer cells (Grier
et al., 1987; Vogel and Mu¨ller-Eberhard, 1981). CVF has thus
also become a gold standard for assessing the inhibitory effect
of experimental anticomplementary agents (Hughes et al.,
1992; Morgan and Harris, 2003; Morganroth et al., 1989, 1986).
Figure 1. Similarities and Differences
between CVF and C3b
(A) Cartoon representation of similarity and differ-
ences in the C3-convertase formation by CVF
and C3b. CVF, cobra venom factor; B, factor B;
vWFA, von Willebrand factor A domain; SP, serine
protease domain; FH, factor H; FI, factor I; DAF,
decay accelerating factor; Ba, N-terminal smaller
fragment of B that consists of three CCPmodules;
Bb, C-terminal fragment of B that consists of
vWFA and SP domains; C3b, the active proteolytic
product of C3; C3c, the inactive proteolytic
product of C3; CUB, complement C1r/C1s, Uegf,
Bmp1 domain; TED, thioester-containing domain.
(B) Schematic representation of chain structures
of Pro-CVF and CVF and its homologous C3,
C3b, and C3c. Pro-C3 is processed into mature
two-chain C3 by the removal of four arginine
residues (646–649). The pro-CVF is processed
into its mature three-chain CVF (a, b, and g chain)
by proteolytic removal of C3a (632–710)- and C3d
(963–1241)-like domains and four arginine
residues (628–631). The arrows with two heads
indicate disulfide bridges.
The three-dimensional structure of
several complement proteins has been
determined, particularly those of the
closely related human C3 (Janssen
et al., 2005), C3b (Janssen et al., 2006;
Wiesmann et al., 2006), C3c (Janssen
et al., 2005), C5 (Fredslund et al., 2008),
bovine C3 (Fredslund et al., 2006), and
insect thioester protein (TEP) (Baxter
et al., 2007). However, the crystal struc-
ture of CVF, a protein that has been
used extensively in complement research
in both in vitro and in vivo experiments,
has not been reported. Here we present
the crystal structure of deglycosylated
CVF (dCVF) and we discuss its structural
and functional similarities and differences
from C3b. In contrast to C3b crystal
structure (Janssen et al., 2006), the
thioester-containing domain (TED) is
missing in the present dCVF crystal
structure, and its complement C1r/C1s,
Uegf, Bmp1 (CUB) domain is positioned
in identical position and the flexible C345c domain is seen shifted
toward the CUB domain.
RESULTS AND DISCUSSION
CVF Crystal Structure
The crystal structure of CVF was determined by molecular
replacement methods and refined using 2.6 A˚ resolution diffrac-
tion data. The crystal structure of C3c (Janssen et al., 2005) and
its individual domains were used as starting search models (see
Experimental Procedures for details). The three chains of CVF
together form 11 domains (Figures 2A and 2B) with overall612 Structure 17, 611–619, April 15, 2009 ª2009 Elsevier Ltd All rights reserved
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Crystal Structure of Cobra Venom FactorFigure 2. The Crystal Structure of CVF
(A) The ribbon diagram of overall CVF crystal structure (left) and its 180 rotated view (right). The a chain formsMG1 (gray), MG2 (indigo), MG3 (blue), MG4 (green),
MG5 (yellow), MG6a (orange), and LNK (red) domains. The g chain forms a’NT (dark green), MG6g (light green), MG7 (cyan), and CUBg (red) domains. The b chain
forms CUBb (blue), MG8 (magenta), ANK (orange), and C345c (red) domains.
(B) Schematic representation of CVF domains (colored as in the ribbon diagram of the crystal structure in [A]). The chain ends are labeled. The connected lines and
arrows indicate disulfide bridges and glycosylation sites, respectively. The secondary structure details and domain boundaries are presented in Figure S1.dimensions of 150 3 76 3 66 A˚ and the domain arrangement
is similar to C3b (Janssen et al., 2006). In contrast to C3b, which
displays one domain made of two chains, two CVF domains are
formed by two chains. One domain is composed of regions from
the a and g chains, whereas the other is composed of g- and
b-chain regions.
The core of the CVF structure is formed by eightmacroglobulin
(MG1–8) domains. MG1–5 domains are formed by the N-terminal
residues of the a chain, whereas MG7 and MG8 domains are
formed by residues from the g and b chain, respectively. The
MG6 domain is formed by residues from both the a (MG6a)
and g (MG6g) chain. The six MG domains (MG1–6) form the
so-called key b ring, the body of the structure. The a chain is
linked to the g chain via an inter-chain disulfide bridge (a522C-
g779C) near the MG5-MG6 interface. The a’NT-like segment is
formed by the N-terminal residues of the g chain, and a linker
(LNK) region formed by residues of the a chain traverses the
b ring. The LNK region consists of three helices in an extended
configuration and one b strand that align with the first strand of
MG1. The C-terminal end of LNK is stabilized by a disulfide
bond (587C-622C) at the end of the second helix. The CUB
domain formed by residues from both the g (CUBg) and
b (CUBb) chain is inserted between the MG7 and MG8 domains.
Finally, the C-terminal C345c domain formed by residues of the
b chain, containing six intra-chain disulfide bridges, is covalently
linked toMG8 via an anchor (ANK) region and toMG7by an inter-
chain disulphide bond (g835C-b1470C). The ten domains of CVFStructure 17(MG1–8, LNK, and C345c) are arranged similar to C3c, whereas
the CUB domain is placed like an extended arm and is located in
a way similar to that seen in the C3b structure (Janssen et al.,
2006), even though the TED is absent. In summary, the core of
CVF is similar to C3b and C3c, but the CUB and C345c domains
of CVF, which are implicated in ligand binding, differ in composi-
tion and location, as the latter is rotated toward the former
domain by about 38 when compared to C3b and C3c (Figure 3).
In all the published structures of human C3, C3b, C3c, and C5,
bovine C3, and TEP the MG1–6 (b-ring core) domains and LNK
form a stable platform, although subtle differences exist among
them; for example, the b-ring core displays amore open arrange-
ment in the TEP structure (Baxter et al., 2007). Superposition of
the b-ring MG1–6 domains and LNK of CVF on related C3c and
C3b structures yields an rmsd of 1.6 A˚ for 598 common Ca
atoms. Difference electron density map (>7s) revealed
a calcium-binding site with six ligands at the center of the key
b ring near the MG5-MG6 interface. The coordination for this
calcium ion comes from MG5 (side chains of Asp517 and
Asp520 and main-chain carbonyl oxygen atoms of Val518 and
Pro494), LNK region (side chain of Glu581 through a water mole-
cule), and one weakly occupied water molecule. The average
bond length of the calcium ion to its ligand O atoms is 2.35 A˚.
Comparison with C3b and C3c
Because CVF is functionally similar to C3b and suggested to
have C3c-like structure, we restrict comparisons of CVF to, 611–619, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 613
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and TEP have suggested that all members of the a2M super-
family have similar architecture and their comparison with
active C3b and inactive C3c has been discussed previously.
The CVF structure displays all C3b domains except the TED
domain (Figure 3B). The eight homologous (MG1–8) domains
that represent the core of CVF align with the corresponding
domains of C3b quite well (see Table S1 available online). For
most of them there are small variations in orientation, transla-
tion, and rmsd (Figures 3A and 3B). The MG1 domain of CVF
displays a disordered EF loop similar to that of C3b MG1, but
has density for an additional three residues in the C-terminal
end of the loop. The MG2 domain of CVF has a disordered
BC loop, though this loop is surrounded by MG1, MG5, MG6,
and LNK domains where its C-terminal part is exposed to the
surface. However, the corresponding loop of C3b is ordered.
The MG3 domain of CVF is very similar to that of C3b and
density is seen for the EF loop in CVF MG3, unlike its absence
in the C3b structure. The CC’ loop of the CVF MG4 domain
deviates toward the core of the domain compared to C3b.
The FG loop of the MG5 domain is five residues shorter than
the C3b MG5, where it is extended toward the MG4-MG5
linker.
Figure 3. Comparison of CVF with C3c
and C3b Structures
(A) Ribbon diagrams of C3c (left), CVF (middle),
and C3b (right). C3c and C3b are made of two
chains, b (green) and a (red), whereas CVF is
composed of three chains, a (yellow), b (magenta),
and g (cyan).
(B) Schematic depiction of domain organizations
of C3c, CVF, and C3b (colored according to chains
as in the ribbon in (A).
The MG6 domain is made up of two
chains in both CVF and C3b. The MG6
of CVF (Figure 4A) is formed by the
a and g chains, whereas in C3b it is
formed by the a and b chains. The simi-
larly positioned MG7 domain in C3b and
CVF is connected to the ANK region via
a disulfide bridge in CVF (g835C-
b1470C) and C3b (b851C-b1491C). The
MG8 domain of CVF is formed by the
b chain, similar to C3b. A structurally vari-
able segment that is not part of the MG
core fold is inserted between bC and
bC’ of the MG fold and has been
observed in the MG8 domain of the C3b
and C3c structures with conformation
b-a-a motif. This segment has also been
observed in the structure of the isolated
RBD region of a2M and is considered
important for the a2M receptor binding
(Jenner et al., 1998). This segment in
C3b is thought to be involved in binding
of properdin that stabilizes the C3bBb
(C3-convertase complex). Notice that
a b-a-b motif is observed for this segment in the C3 structure
to which properdin is not binding. In CVF, the conformation of
this segment is a b-a motif followed by an extended loop and
a b sheet of two short antiparallel b strands. The LNK and ANK
regions of CVF are similarly positioned to those in C3b and
C3c. The ANK region of CVF connects the C345c domain to
the core of the molecule via a peptide bond to MG8 and via
a disulfide bond (835C-1470C) to MG7 as in C3b. This disulfide
bond is an inter-chain bond in CVF linking b and g chains. The
ANK region of CVF has an additional intra-chain disulfide bond
(1463C-1468C) as observed in C3b. The region undergoes
a drastic conformational change during the conversion of C3 to
C3b from an a helix to a b hairpin, apparently not restricted by
the internal disulfide bond (Janssen et al., 2005, 2006).
CUB Domain
The CUB domain and its conformation deserve special attention.
The CUB domain in CVF is formed by the segments from g (896–
945) and b (1252–1311) chains (Figure 4B) and in C3b it is formed
by two distinct parts (913–963 and 1270–1329) of the a chain
(Janssen et al., 2006)(Figure 4C). The C-terminal segment after
MG7 domain in the g chain and the N-terminal segment
preceding MG8 domain of the b chain constitute the CUB614 Structure 17, 611–619, April 15, 2009 ª2009 Elsevier Ltd All rights reserved
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domain inserted between its b5-b6 loop, connects MG7 to
MG8 of a chain. There is a glycosylation site at position 917 on
the CUB domain of C3b, which is absent in CVF. The electron
density is clear for the core b strands of the CVF CUB domain,
although the connecting loops have weak density. Its conforma-
tion and position relative to the remaining domains are similar to
those of the CUB domain of C3b (Janssen et al., 2006), except
that the CVF CUB domain is translated by 3 A˚ with 15.5 rotation
compared to theC3bCUBdomain.Maybe because of its solvent
accessibility and freedom from packing constraints, the CUB
domain in CVF exhibits higher temperature factors with poorer
Figure 4. Topology Diagrams of Intertwined
Domains of CVF and C3b
(A) CVF MG6 is made of the a (orange) and
g (green) chains. The terminals of the domains
are labeled.
(B) CVF CUB is composed of the g (red) and
b (blue) chains.
(C) C3b CUB domain is composed of two distinct
parts of a chain.
electron density, especially for many
side chains compared to all other
domains. However, disordered regions
are often functional and may play a role
in the assembly of macromolecular
arrays (Dyson and Wright, 2005).
C345c Domain
The C345c domain at the C-terminal
end is common to the complement
proteins C3, C4, and C5, but absent
from other members of the a2M family.
The C345c domain of CVF is formed by
the C-terminal region of the b chain; it is
connected to MG8 covalently via the
ANK region and to the MG7 domain via
a disulfide bridge as in C3b. Superposi-
tion of the C345c domain structure on
that of C3b and C3c yields an rmsd of
1.0 A˚ for 129 common Ca atoms. This
domain is translated by 5.2 and 7.7 A˚
and rotated by 38.5 and 36.9 toward
the CUB domain, compared to C3b and
C3c, respectively. The electron density
for this domain is relatively weak
compared to other domains but better
defined than the CUB domain. This may
be partly due to weak crystal lattice
contacts and relative mobility that is
also observed in the C3c, C3b, C3, and
C5 structures.
Convertase Formation
The catalytic activity of the C3-conver-
tases C3bBb and CVFBb is mainly due
to the proteolytic apparatus provided by
the serine protease factor B, the primary ligand for CVF. Many
studies have investigated the factor B interaction sites on C3
and C3b, but not on CVF. Therefore, the binding site for factor
B on CVF has to be defined in comparison to C3b. Multiple C3b
sites have been proposed for factor B binding. Residues
730DEDIIAEENT739 at the a’NT region of C3b that include four
acidic residues (730DE and 736EE) have been indicated as the
major binding site by peptide binding and mutagenesis studies
(Becherer et al., 1992; Clemenza and Isenman, 2000; Tanigu-
chi-Sidle and Isenman, 1994). Analogously, it has also been
proposed that the N terminus of the C4 a’ chain is a binding site
for C2 (Pan et al., 2000). In bovine and humanC3, the a’NT regionStructure 17, 611–619, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 615
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et al., 2006; Wiesmann et al., 2006). In the CVF structure, the
structurally equivalent region 714EDGFIADSDI723 is found at the
N-terminal end of the g chain occupying the same position as
the a’NT region of C3b and C3c (Figure 5). Thus, two clusters of
acidic residues on C3b are also present in CVF at the N-terminal
end of the g chain (714DE and 720DSD). Additionally, CVF has one
more acidic acid cluster at the very beginning of the g chain
(711DDN), whereas the equivalent region of C3b is 727SNL. The
above two clusters of acidic residues present in C3b are also
present in C3c. However, C3c does not bind factor B, suggesting
that additional sites are needed for factor B binding. The efficient
binding of factor B by CVF, which is structurally similar to C3
except for the presence of the CUB domain, suggests a role for
CUB in factor B binding.
O’Keefe et al. (1988) identified another possible site for factor
B binding when they characterized the C3o fragment produced
by cleavage of C3 by a cobra venom protease. C3o resembles
C3c, but unlike C3c it can form a C3 convertase with factor B.
N-terminal sequencing and molecular weight comparisons of
C3c and C3o suggested that residues 933EGVQKEDIPPA943 at
the N terminus of C3dg might be responsible for the difference
in activity. In the C3b structure, the aforementioned region forms
the b4 strand and the flanking loops of the CUB domain. The
structurally corresponding region 917GGTQLEVIKARK927, more
polar and charged, in the CVF (Figure 5) is located at the
C-terminal end of the g chain on the b4 strand of the CUBg
half of CUB. The CUB domain is extended downwards from
the head during C3b formation (Janssen et al., 2006) and in
CVF it is located in a similar position, except for the small devia-
tiondiscussed above, suggesting similar binding sites for factor B.
It has been suggested that residues 1496–1641 at the
C terminus of the C345c domain are involved in the factor B
binding (Kolln et al., 2005). The suggestion was based on exper-
iments replacing various segments of C345c with the corre-
sponding regions of CVF, which resulted in enhanced lifetime
of the C3bBb-convertase complex. However, the C345c domain
of CVF is translated and rotated compared to C3b and C3c as
Figure 5. Proposed Factor B Binding Sites
These sites are indicated (in gold) on the structure
of CVF (only the top half of the molecule is shown).
The small panel depicts the CVF site a’NT (gold)
in comparison with the corresponding sites of
C3b (green) and C3c (red).
mentioned above (Figure 3). Hence, in
addition to the specific residue differ-
ences between C3b and CVF in the
C345c domain, its relative position to
the CUB domain may also have an affect
on the stability of the C3-convertase
complex.
In C3b and CVF, the three sites a’NT,
CUB, and C345c are located on the
same side of the molecule and near to
each other, like corners of a triangle. In
CVF, the a’NT and C345c are separated
by 40 A˚, whereas CUB is placed 60 A˚
away from each of the other two domains. Factor B consists
of 739 amino acids (90 kDa) that form three modules. The
N-terminal smaller module Ba, which is removed during conver-
tase formation, consists of three complement control protein
(CCP1–3) domains (Figure 1A). The C-terminal major fragment
Bb consists of a von Willebrand factor A (vWFA) domain and
aserineprotease (SP)domain (Figure 1A). ProposedC3b-binding
sites are foundon all threeCCPsof Ba (Hourcade et al., 1995), the
MIDAS of vWFA domain (Hinshelwood et al., 1999; Hourcade
et al., 1999; Sa´nchez-Corral et al., 1990), and the SP domain
(Lambris and Mu¨ller-Eberhard, 1984). Analogously, multiple
C4b-binding sites have also been proposed on C2 (Laich and
Sim, 2001), located on all three CCP domains (Xu and Volanakis,
1997), and the MIDAS motif of the vWFA domain (Horiuchi et al.,
1991). Various studies have shown an acidic residue of the ligand
that completes the coordination sphere of the divalent ion bound
at theMIDAS (Emsley et al., 2000; Shimaoka et al., 2003), and it is
expected that such a residue be located in the a’NT. The
conformational changes induced in the vWFA and SP domains
of C3b- or CVF-bound factor B upon removal of Ba are irrevers-
ible. Once dissociated, Bb can no longer associate with C3b. The
distance (44 A˚ in FB and 55 A˚ in Bb) between the MIDAS and
the positively charged L2 loop of the SP domain of Bb corre-
sponds to the above sites on CVF. Therefore, two of the above
sites of CVF could be the binding sites for flexible SP and vWFA
domain while the third site could be the binding site for CCP
modules during the initial convertase formation.
Two additional sites for factor B binding on C3b have been
proposed. The first, analogous to a C2-binding site on C4 (Inal
and Schifferli, 2002; Oh et al., 2003), is formed by the bG strand
of MG2, the bA strand of MG3, and the MG2-MG3 linker loop.
The corresponding residues 192–212 in CVF (Figure 5) and
C3b (200–220) are on the buried side of the CUB domain and
relatively inaccessible. Conformational changes in the b ring
may make this site accessible. The second site that has been
implicated is present on the C3d domain of C3b (Koistinen
et al., 1989; Lambris et al., 1988); however, CVF does not carry
a C3d-like domain, thus excluding this possibility.616 Structure 17, 611–619, April 15, 2009 ª2009 Elsevier Ltd All rights reserved
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Several regulatory proteins (factor H, complement receptor 1
[CR1], decay-accelerating factor, membrane cofactor protein,
and factor I) prevent assembly and dissociate the C3bBb
complex and/or act as cofactors for proteolysis of C3b by factor
I. Fishelson (1991) suggested that the 744EFPESWLWNVE754
region at thea’NTofC3bcontributes to factorHandCR1binding.
Two acidic residues, 744E and 747E, in that segment located in the
MG6 domain were found important for factor H and CR1 binding.
In CVF, the corresponding segment 728DFPKSWLWLTK738 has
one acidic residue, 728D , whereas the second one is replaced
by a lysine, 731K, which possibly explains the inability of CVF to
bind factor H and CR1. Moreover, residues 1187–1249 of the
C3b a chain provide at least one additional site for factor H
binding (Janssen et al., 2006; Jokiranta et al., 2000; Koistinen
et al., 1989; Lambris et al., 1988). This segment forms helices
a9–a11 and neighboring loops in the TED domain. Because
the TED domain is not present in the CVF, factor H loses an
additional potential binding site. Consequently, the decay accel-
eration of the CVFBb complex by factor H and CR1 is prevented,
contributing to its stability in serum.
Properdin, a 45 kDa protein, binds to the C3-convertase
C3bBb, significantly extending its half-life. A binding site for
properdin has been proposed to be at residues 1402–1435 in
the C terminus of the C3 a chain, which forms the structurally
variable MG8 b-a-b motif converted to a b-a-a motif in C3b
and C3c. The corresponding site in the CVF is at residues
1381–1414 of the b chain. This loop is exposed as in C3b and
retains its hydrophobic nature, but deviates in secondary
structure as the segment displays a loop element with a short
b sheet after the b-a motif.
Conclusion
It appears that the CUB domain, which in CVF occupies the
same position as in C3b, probably plays a vital role in the forma-
tion of C3-convertases CVFBb and C3bBb by providing an
important primary binding site for factor B. The C345c domain
exhibits considerable differences in its position and orientation
between CVF and C3b, suggesting a possible role for the higher
stability of the CVFBb complex. However, the position of the
C345c domain seems to be influenced by molecular packing in
many of the similar protein structures. No significant differences









Completeness (%) 92.8 (76.6)
Redundancy 7.1 (2.1)
I/sI 21.7 (2.0)
Values in parentheses refer to the outermost resolution shell.
a Rmerge = Shkl Sj j Ij  <I> j / Shkl Sj Ij, where <I> is the mean intensity of
j observations from a reflection hkl and its symmetry equivalents.Structure 17,are observed among the CVF, C3b, and C3c structures in the
position and composition of the a’NT and the same holds true
for the MG2-MG3 interface; hence these regions are expected
to play a minor role in the formation and stability of the conver-
tases. The segment 730DEDIIAEENT739 in the a’NT may provide
a binding site but that may not be enough for factor B and Bb
binding, since C3c, which does not bind factor B, also has the
a’NT region at the same position. Moreover, C3o lacks residues
727–736 of the a’NT but supports C3-convertase formation,
perhaps because it retains residues 933–942 of theCUBdomain.
In both CVF and C3b crystal structures these residues are
present on the CUB domain surface at the C-terminal end of
a b strand that is physically closer to C345c domain. If this
stretch of residues has a role in factor B binding (O’Keefe
et al., 1988), the charged nature of this b strand in CVF in contrast
to the hydrophobic environment present in C3b (Janssen et al.,
2006) may suggest some bearing on the binding and affinity of
CVF toward Bb. The predicted factor B-binding site (Fishelson,
1991) in the C3d domain could be an additional binding site
but probably is not essential because of its absence in CVF.
Factor B may interact with a’NT, CUB, and C345c domains
through multiple binding sites, and at least two of them, one in
Ba and another in the middle vWFA domain, have been identi-
fied. Resistance of CVF to regulatory proteins is apparently
due to the absence of the C3d domain, which provides binding
site(s) for them. In conclusion, the presence of the CUB domain
and the absence of the TED domain in CVF, when compared to
C3c and C3b, reveals some possible reasons why the CVFBb
complex ismore stable and escapes from the regulatory proteins
during complement activation in plasma.
EXPERIMENTAL PROCEDURES
Protein Purification
CVF was isolated from lyophilized Naja naja kouthia cobra venom using
published methods (Vogel and Mu¨ller-Eberhard, 1984; Sharma et al., 2001).
Briefly, 200 mg of cobra venom was dissolved in 1 ml of 50 mM Tris-HCL
and 100 mM NaCl (pH 7.5) and mixed at room temperature for 10 min. The
sample was then centrifuged at 18,000 for 10 min and the cleared supernatant
was applied to a Sephacryl S-200 (16/60) column (Pharmacia) in the same
buffer. The second elution peak containing the CVFwas collected and dialyzed
overnight against 50 mM Tris-HCL (pH 8.5). This was subsequently applied to
a DEAE Bioscale column (BioRad) and eluted with a linear gradient to 1MNaCl
(Sharma et al., 2001). Fractions containing CVF were combined for deglycosy-
lation. The deglycosylation was carried out using PNGase F (New England
BioLabs, Inc.) according to the manufacturer’s instructions. The dCVF was
further purified by gel-filtration chromatography and dialyzed against 25 mM
phosphate buffer (pH 6.5) and concentrated to 7 mg/ml. Purity of dCVF was
examined by SDS-PAGE analysis. Activity was assayed and confirmed by
hemolytic assay (Vogel and Mu¨ller-Eberhard, 1984).
Crystallization and Data Collection
Rod-shaped dCVF crystals were obtained through sequential seeding in
hanging drops equilibrated against 1 ml of reservoir solution containing 13%
PEG 3350, 10 mM MES (pH 6.8), 5 mM CaCl2, and 200 mM NH4Cl at 20
C.
Crystals were flash-cooled in liquid nitrogen using 30% ethylene glycol plus
the well solution containing 15% PEG 3350 as a cryoprotectant. The dCVF
crystals diffracted to 2.6 A˚ on the SER-CAT BM beam line (Advanced Photon
Source). However, crystals were sensitive and suffered from radiation damage
and anisotropic decay. Hence, multiple crystals were used for data collection.
Processed and scaled with HKL2000 (Otwinowski et al., 2003), diffraction data
from three crystals were scaled to obtain a single and suitable data set for the
structure determination (see Table 1 for statistics). Data set is complete to611–619, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 617
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Crystal Structure of Cobra Venom Factor2.8 A˚ resolution and completeness dropped to 75% in the last resolution shell.
Crystals exhibited space group P21212 with onemolecule per asymmetric unit.
Structure Determination
The structure was determined by molecular replacement methods with
PHASER (McCoy et al., 2005; Read, 2001; Storoni et al., 2004), using individual
domains of C3c as starting search models. The key MG1-MG6 b ring was first
located and the remaining domains of C3c, i.e., MG7, MG8, and C345C, were
added one after another. After placing all other domains by PHASER, search
and building of the CUB domain was carried out with the help of CUB domain
model of C3b and sequential difference electron density maps. Electron
density for the CUB domain was weak initially but improved gradually over
multiple cycles of model building done with the help of difference and omit
maps. Rigid body refinement was done using CNS (Brunger et al., 1998),
model fitting with COOT (Emsley and Cowtan, 2004), and final refinement
using REFMAC (Murshudov et al., 1997). After the final cycle of refinement,
the model had Rwork value of 24.7% and Rfree of 29.7% (see Table 2 for statis-
tics and Figure S2 for the quality of the electron density maps).
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Atomic coordinates and structure factors have been deposited in the
Research Collaboratory for Structural Bioinformatics Protein Data Bank under
the ID code 3FRP.
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this article online at http://www.cell.com/structure/supplemental/
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ACKNOWLEDGMENTS
This project is supported by National Institutes of Health grant AI1064815
to S.V.L.N.
Received: November 13, 2008
Revised: January 27, 2009
Accepted: January 27, 2009
Published: April 14, 2009
Table 2. Refinement Statistics for dCVF Structure
Resolution range (A˚) 50–2.6
Rwork/Rfree (%)
a 24.7/29.7
Rmsd for bonds (A˚) 0.011
Rmsd for angles () 1.323
Number of non-hydrogen atoms 9158
Number of water molecules 80
Number of metal ions (calcium) 1
Wilson B factor (A˚2) 68.7





Ramachandran plot (favored/allowed/disallowed) (%) 85.7/14.1/0.2
a Rwork = Shkl j jFobsj  jFcalcj j / Shkl jFobsj, where Fo and Fc and
are measured and calculated structure factors, respectively. Rfree was
calculated using 5% of data that were omitted from refinement.
b The count excludes 5% test data set (2221 reflections) used in the
refinement.618 Structure 17, 611–619, April 15, 2009 ª2009 Elsevier Ltd All righREFERENCES
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